Core Viewpoint - The article highlights the successful financing of Shanghai Tianyin Biotechnology Co., Ltd., which has raised over 10 million RMB, indicating increased capital market attention towards the emerging field of psychological health detection and intervention [2][14]. Company Overview - Tianyin Biotechnology is an innovative medical technology company incubated from research achievements at Shanghai Jiao Tong University, focusing on early screening, precise assessment, and personalized intervention for mental health disorders [4]. - The company aims to transition psychological health from a "soft science" to an "objective medicine" by integrating biological mechanisms, medical devices, and AI algorithms [4]. Core Innovation - The company's key breakthrough is the development of the world's first objective biological detection technology for clinical intervention guidance, known as the Skin Nicotinic Acid Reaction (NSR) test [5]. Technology and Product System - The NSR technology allows for real-time assessment of skin cell membrane function, enabling non-invasive psychological health risk identification within 5 minutes, overcoming the limitations of traditional subjective psychological assessments [7]. - Tianyin has established a comprehensive product system covering "risk screening—medical testing—personalized intervention—health management," differentiating itself from traditional psychological assessment companies and online consultation platforms [8]. Market Trends - The psychological health detection field is shifting from subjective methods to objective assessments, with the World Health Organization reporting over 300 million depression patients globally and a 6.8% prevalence rate of depressive disorders in China [14]. - The NSR technology aligns with public health screening needs, as various regions in China are incorporating psychological health assessments into public health systems [17]. Market Landscape - The global market for objective psychological health detection is still in its early stages, with Tianyin being the first domestic company to obtain an innovative medical device registration certificate in this field, establishing a significant technological barrier and clinical progress [18]. - Future competition is anticipated as the market matures, with potential entrants from imaging detection firms, wearable device companies, and traditional psychological assessment platforms [18]. Challenges and Observations - Despite the promising outlook, the commercialization of psychological health detection faces challenges such as high market education costs, incomplete insurance payment mechanisms, regulatory and ethical issues, and accelerating competition [22]. Conclusion - The financing and technological advancements of Tianyin Biotechnology signify a shift in the psychological health industry from "soft services" to "hard technology," with the NSR technology providing a new pathway for early screening and risk assessment in mental health [20].